Cost-effectiveness of home-based vs. in-hospital treatment of paediatric tuberculous meningitis

S. L. Van Elsland*, S. I. Van Dongen, J. E. Bosmans, H. S. Schaaf, R. Van Toorn, A. M. Van Furth

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


SETTING: Cape Town, South Africa, 2014. OBJECTIVES: To assess the societal costs and cost-effectiveness of home-based vs. in-hospital treatment of paediatric tuberculous meningitis. DESIGN: This was an economic evaluation from a societal perspective using probabilistic analysis. Health care, informal care, lost productivity costs and costs in other sectors, health-related quality of life (HRQoL) and family impact were assessed during interviews with care givers, children, medical staff and management. RESULTS: Societal costs for home-based treatment were USD3857, and USD28 043 for in-hospital treatment. Home-based vs. in-hospital treatment HRQoL scores were 90.9% vs. 84.5%, while family impact scores were 94.8% vs. 73.1%. The point estimate of the incremental cost-effectiveness ratio indicated that improving HRQoL and family impact by 1% was associated with a saving of respectively USD3726 and USD1140 for home-based vs. in-hospital treatment. The probability that home-based treatment was less expensive and more effective than in-hospital treatment was 96.3% for HRQoL and 100% for family impact. CONCLUSIONS: Societal costs of home-based treatment were lower than for in-hospital treatment. Children treated at home had a better HRQoL and family impact scores. Home-based treatment was a cost-effective alternative to in-hospital treatment of drug-susceptible tuberculous meningitis.

Original languageEnglish
Pages (from-to)1188-1195
Number of pages8
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number10
Publication statusPublished - 1 Oct 2018

Cite this